Amylin – Talk Bio

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

5 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

5 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership

10 months ago talkbio0Tagged Amylin, Billion Raise, Obesity, Partnership, Weight Loss, Zealand Pharma

Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership